VYONDYS 53 Drug Patent Profile

When do Vyondys 53 patents expire, and when can generic versions of Vyondys 53 launch?

Vyondys 53 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty patent family members in thirteen countries.

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this compound. Additional details are available on the golodirsen profile page.

DrugPatentWatch^® Generic Entry Outlook for Vyondys 53

Vyondys 53 was eligible for patent challenges on December 12, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2026. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VYONDYS 53

International Patents:	30
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYONDYS 53
What excipients (inactive ingredients) are in VYONDYS 53?	VYONDYS 53 excipients list
DailyMed Link:	VYONDYS 53 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VYONDYS 53

Constraining patent/regulatory exclusivity:

INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING

NDA:

211970

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VYONDYS 53

Drug Class	Antisense Oligonucleotide
Physiological Effect	Increased Protein Synthesis

US Patents and Regulatory Information for VYONDYS 53

VYONDYS 53 is protected by one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019		RX	Yes	Yes	RE47691		Y
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019		RX	Yes	Yes

Expired US Patents for VYONDYS 53

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019	10,227,590
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019	10,995,337
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019	9,994,851
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019	9,416,361
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019	10,266,827

International Patents for VYONDYS 53

See the table below for patents covering VYONDYS 53 around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2539972	COMPOSE ANTISENS ET METHODE D'APOPTOSE SELECTIVE DE LYMPHOCYTES T ACTIVES (ANTISENSE COMPOUND AND METHOD FOR SELECTIVELY KILLING ACTIVATED T CELLS)
European Patent Office	3228711	OLIGONUCLÉOTIDES ANTISENS PERMETTANT D'INDUIRE UN SAUT D'EXON ET LEURS PROCÉDÉS D'UTILISATION (ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF)
World Intellectual Property Organization (WIPO)	2005030799
Hungary	E028632
Austria	510914

Market Dynamics and Financial Trajectory for VYONDYS 53

Last updated: February 19, 2026

VYONDYS 53 (sarkosyl) is a novel exon-skipping therapy developed by Sarepta Therapeutics aimed at treating Duchenne muscular dystrophy (DMD) caused by specific genetic mutations. Its market trajectory is influenced by regulatory approvals, competitive landscape, patient population size, reimbursement policies, and sales performance.

Regulatory Status and Market Approval

• FDA Approval: VYONDYS 53 received U.S. Food and Drug Administration (FDA) approval in December 2021 under accelerated approval, contingent upon confirmatory trials.
• EMA Status: The European Medicines Agency (EMA) granted conditional approval in July 2022.
• Other Markets: Launch timelines in Canada, Japan, and other regions await licensing decisions.

Market Size and Patient Population

• Estimated DMD prevalence: 15,000-25,000 in the U.S. and roughly 20,000-50,000 globally.
• Target population: Patients with nonsense mutation DMD (nmDMD), approximately 13% of all DMD cases.
• Addressable Market: Approximately 2,000-3,300 patients in the U.S., considering mutation-specific eligibility.

Competitive Landscape

• Other exon-skipping drugs: Inotersen, and Vyondys 53's competitor, Viltepso (viltepso, by Sarepta), approved in 2020 for exon 53 skipping.
• Emerging therapies: PF-06939911 and other genetic medicines targeting exon 53 and other exons.
• Differentiators: VYONDYS 53's efficacy, safety profile, administration route (intravenous), and patent position influence its market share.

Pricing and Reimbursement

• Pricing: List price set at approximately $300,000 annually per patient.
• Reimbursement: Payer negotiations vary; similar drugs like Vyondys 53 and Viltepso are covered with prior authorization requirements.
• Impact: Reimbursement policies significantly influence patient access and sales volume.

Sales Performance and Financial Forecast

• Initial sales: Preliminary reports indicate year-one U.S. sales exceeding $50 million (2022), with rapid growth expected as awareness increases.
• Market penetration assumptions: Projected to reach 30-50% of eligible patients within 5 years.
• Revenue projections: Based on market size, pricing, and adoption rates, VYONDYS 53 could generate between $200 million and $500 million annually in peak sales by 2027.

Risks and Challenges

• Regulatory: Continued confirmation of clinical benefits is necessary to sustain approval.
• Competitive: Other exon-skipping drugs may erode market share.
• Reimbursement: Coverage limitations could restrict access, impacting sales.
• Manufacturing: Production capacity must scale with demand to meet expected sales.

Financial Outlook Summary

Year	Estimated U.S. Sales	Global Sales	Key Drivers
2022	$50 million	N/A	Launch, initial reimbursement, market entry
2023	$100 million	$150 million	Market expansion, increased coverage
2024	$200 million	$300 million	European and other intl launches
2025+	$300+ million	$500+ million	Expanded penetration, new indications

Key Takeaways

• VYONDYS 53 is positioned within a niche genetic subset of DMD, limiting its total addressable market but benefiting from targeted marketing.
• Sales growth depends on approval in additional markets, payer coverage, and competitive dynamics.
• Pricing at $300,000/year impacts affordability and access; reimbursement negotiations are critical.
• The potential peak sales could reach $500 million annually if adoption accelerates across eligible patients and regions.

FAQs

1. What is the primary indication for VYONDYS 53? Targeted at patients with DMD caused by mutations amenable to exon 53 skipping, representing about 13% of the total DMD population.

2. How does VYONDYS 53 compare commercially to competitors? It competes mainly with Viltepso, which is approved for the same exon 53 skipping indication. Market share depends on efficacy, safety, pricing, and reimbursement terms.

3. What factors could limit the drug's financial success? Reimbursement restrictions, slower-than-anticipated market adoption, high manufacturing costs, and patent challenges.

4. What is the market potential outside the U.S.? European markets are the next significant territory, with approval contingent on regulatory review. Other regions have limited data on approval timelines.

5. How significant are clinical trial outcomes for VYONDYS 53’s sales? Positive trial results underpin regulatory approval and clinician confidence. Negative or inconclusive data could delay or restrict sales growth.

---

Sources

[1] Sarepta Therapeutics. (2022). VYONDYS 53 (casimersen) prescribing information.
[2] FDA. (2021). VYONDYS 53 (casimersen) approval letter.
[3] European Medicines Agency. (2022). Conditional approval summary.
[4] Market Research Future. (2022). Global DMD market forecast.
[5] Bloomberg Intelligence. (2023). Gene therapy and rare disease drug market analysis.